Amphastar Pharma (AMPH) Tops Q2 EPS by 11c
Tweet
Share
E-mail
Get Alerts AMPH Hot Sheet
Join SI Premium – FREE
Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.85, $0.11 better than the analyst estimate of $0.74. Revenue for the quarter came in at $174.4 million versus the consensus estimate of $173.95 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Starts Arrowhead Pharma (ARWR) at Buy
- Cadrenal Therapeutics (CVKD) files for 2.94M share offering by sellign stockholders
- Gyre Therapeutics (GYRE) files for 31.03M share offering by selling stockholders
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
